# Bromocriptine in the Treatment of Peripartum Cardiomyopathy

> **NCT02590601** · PHASE3 · WITHDRAWN · sponsor: **Montreal Heart Institute**

## Conditions studied

- Peripartum Cardiomyopathy

## Interventions

- **DRUG:** Bromocriptine
- **OTHER:** Guideline-driven medical therapy (GDMT)

## Key facts

- **NCT ID:** NCT02590601
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Not enough patients
- **Last updated:** 2023-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02590601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02590601, "Bromocriptine in the Treatment of Peripartum Cardiomyopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02590601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*